LEXEO THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [_______], 20[__], and is between Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
EMPLOYMENT AGREEMENT for PAUL MCCORMACEmployment Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and Paul McCormac (the “Executive”) (collectively, the “Parties”).
RESEARCH AGREEMENTResearch Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Agreement is made by and between Lexeo Therapeutics, Inc. (“Company”) with offices at 430 East 29th Street, 14th Floor, New York, NY 10016, and The Regents of the University of California on behalf of its San Diego campus, having its office at 9500 Gilman Drive, La Jolla, CA 92093-0934, (“University”), (each may be individually referred to as a “Party” and collectively, as the “Parties”), effective as of the date of last signature below (“Effective Date”).
LICENSE AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FORLicense Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This agreement (“Agreement”) is entered into by and between LEXEO Therapeutics, Inc., a Delaware corporation having an address at 430 East 29th Street, 14th Floor, New York, NY 10016 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607- 5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UC San Diego”).
LICENSE AGREEMENT BETWEEN ARVC THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FORLicense Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This agreement (“Agreement”) is entered into by and between ARVC Therapeutics, Inc. a Delaware corporation having an address at 1396 Rubenstein Ave, Cardiff by the Sea, CA 92007 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UC San Diego”).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration Agreement (this “Agreement”), effective as of February 3, 2021 (the “Effective Date”), is entered into by and between Cornell University, for and on behalf of its Joan & Sanford I. Weill Medical College, a New York education corporation with offices at 1300 York Avenue, New York, NY 10065 (“WCM”), and LEXEO Therapeutics, Inc., a Delaware corporation, having an office at 430 East 29th Street, 14th Floor, New York, NY 10016 (“Company”). WCM and Company each may be referred to herein as a “Party” and together as the “Parties.”
FIRST LICENSE AGREEMENT BETWEEN LEXEO THERAPEUTICS, LLC AND CORNELL UNIVERSITY FOR DOCKET NO. D-6083 DOCKET NO. D-9134 DOCKET NO. D-9179 DOCKET NO. D-9187 DOCKET NO. D-9232 DOCKET NO. D-9325 DOCKET NO. D-9471 DOCKET NO. D-9472 CTL CONTRACT NO. [***]License Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This First License Agreement (this “Agreement”) is made by and between LEXEO Therapeutics, LLC, a Delaware limited liability company, having an office at 430 East 29th Street, 14th Floor, New York, NY 10016 (“LICENSEE”), and Cornell University, a New York education corporation (“Cornell”), as represented by its Cornell Center for Technology Licensing (“CTL”) at 395 Pine Tree Road, Suite 310, Ithaca, NY 14850. Cornell and LICENSEE each may be referred to herein as a “Party” and together as the “Parties.”
ContractLicense Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances)
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
ContractLicense Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances)
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of August 10, 2021, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
